ISRCTN47583497 https://doi.org/10.1186/ISRCTN47583497

Decreased time on mechanical ventilation when comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial.

Submission date 09/02/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 09/02/2005	**Overall study status** Completed	
Last Edited 16/08/2011	**Condition category** Surgery	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Andrew Kirkham

Contact details
GlaxoSmithKline
Greenford Road
Greenford, Middlesex
United Kingdom
UB6 OHE

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
USA30226

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Medical or surgical patients requiring intensive care.

Interventions
Comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients. Titration of analgesia/sedation to achieve optimal sedation. Regular assessments of haemodynamics.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Remifentanil

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
07/06/2002

Completion date
30/06/2003

Eligibility

Key inclusion criteria
Critically ill patients requiring 3-10 days of mechanical ventilation.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
07/06/2002

Date of final enrolment
30/06/2003

Locations

Countries of recruitment
Austria

Belgium

Denmark

France

Germany

Greece

Iran

Netherlands

Portugal

United Arab Emirates

United Kingdom

Study participating centre
GlaxoSmithKline
Greenford, Middlesex
United Kingdom
UB6 OHE

Sponsor information

Organisation
GlaxoSmithKline

Sponsor details
Greenford Road
Greenford
United Kingdom
UB6 0HE

Sponsor type
Not defined

ROR
https://ror.org/01xsqw823

Funder(s)

Funder type
Industry

Funder Name

GlaxoSmithKline (GSK)

Alternative Name(s)
GlaxoSmithKline plc., GSK plc., GSK

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/06/2005		Yes	No